Related Experiment Video
Updated: Sep 13, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Pancreatic ductal adenocarcinoma: Clinical trials to watch
Vincent P Groot1, I Quintus Molenaar2, Geert A Cirkel3
1Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht University, Utrecht, the Netherlands; Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, NYU Grossman School of Medicine, New York, NY, USA.
Abstract:
The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.
